Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
暂无分享,去创建一个
Y. Bang | N. Sugimoto | D. Sakai | Jeeyun Lee | H. Chung | S. Iwasa | K. Shitara | K. Yamaguchi | H. Kawakami | M. Sugihara | H. Yabusaki | Y. Kawaguchi | T. Kamio | A. Kojima | M. Ryu | K. Saito